<DOC>
	<DOCNO>NCT00525408</DOCNO>
	<brief_summary>This study propose comparison overall survival , hematological toxicity , pain reduction score , PSA level , tumor response , quality life two arm HRPC patient different part India .</brief_summary>
	<brief_title>A Study Mycobacterium w Plus Docetaxel Hormone Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description>Prostate Cancer common health issue face men worldwide patient cancer shrink hormonal therapy . In case cancer return continue grow despite low level circulate male hormone , call Androgen-Independent Prostate Cancer ( AIPC ) Hormone Refractory Prostate Cancer ( HRPC ) . Mycobacterium w know share multiple antigen include PSA . It administration associate antigen specific generation cell mediate immunity . Docetaxel find useful management metastatic hormone refractory prostate cancer , associate improved survival , tumor progression free survival reduction pain , serum PSA improvement quality life . Cyclophosphamide 300mg/sq.m use eliminate T-regulatory cell responsible immuno suppression . The vaccine Mycobacterium w administer day follow cyclophosphamide . For good initiation immune response Docetaxel give seven day follow first dose Mycobacterium w .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate clinical radiologic evidence metastatic disease . Disease progression antiandrogen therapy , surgical medical castration status . Karnofsky Performance Status 50100 Normal cardiac function Life expectancy least 24 week . Laboratory criteria eligibility include A neutrophil count least 1500 per cubic millimeter A hemoglobin level least 9 gm % A platelet count least 1000,000 per cubic millimeter . A total bilirubin grater 1.5 time upper limit normal range institution . Serum creatinine level 1.5 time upper limit normal range Written inform consent Prior treatment cytotoxic agent radioisotopes Estrogen use least three month History another cancer within precede five year ( except basal squamouscell skin cancer ) Brain leptomeningeal metastasis Symptomatic peripheral neuropathy grade 2 high Uncontrolled intercurrent illness would limit compliance study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HRPC</keyword>
	<keyword>Metastatic Hormone Refractory Prostate Cancer</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Mycobacterium w</keyword>
</DOC>